10 COVID-19 Vaccines Under Phase III Trials
10 COVID-19 Vaccines Under Phase III Trials
10 COVID-19 Vaccines Under Phase III Trials. According to data from the World Health Organization on November 12, there are currently 10 COVID-19 vaccine projects that have entered The final phase 3 clinical trials came from China, the United States, Germany, the United Kingdom and Russia.
Pfizer: Phase III clinical data show that the protective effect exceeds 90%
The third phase of the trial of the COVID-19 pneumonia vaccine jointly developed by Pfizer and BioNTech of Germany is still in progress, but the test results are quite good, with a protective effect of more than 90%. American infectious disease prevention expert Anthony Fauci is also optimistic that the American people will be vaccinated against the COVID-19 pneumonia by the end of the year at the earliest, and other countries are just around the corner.
In the Phase 3 trial of Pfizer and BioNTech’s COVID-19 pneumonia vaccine, more than 40,000 subjects were vaccinated, and the subjects had to take two doses with a 3-week interval between them. The initial test results came from 94 COVID-19-confirmed subjects. They developed protection after 28 days after the first dose of vaccination; after 7 days after the second dose, the effective protection was more than 90%.
Pfizer vaccines in Taiwan have almost determined that it is difficult to get them in the first place. What can the Chinese people expect? In fact, it is also expected to be on the market at the end of the year, and there is a vaccine from Moderna Biotechnology (Moderna).
Moderna: The COVID-19 vaccine is expected to be available in the United States by the end of the year
Moderna of the United States and the National Institute of Allergy and Infectious Diseases jointly developed the COVID-19 vaccine mRNA-1273. It has entered Phase III clinical trials at the end of July and recruited 30,000 people to participate in the trial. There will be sufficient data support at the end of November. Apply for emergency use authorization.
According to US Fox News, Moderna has signed more than 1.1 billion U.S. dollars agreements with governments around the world. If clinical research proves effective and is approved by the government, 20 million doses of the COVID-19 vaccine will be marketed in the United States by the end of this year and will be launched in 2021. Provide about 500 million to 1 billion doses of vaccine.
Foch said that Moderna’s vaccine is “almost the same” as Pfizer’s, so it would be reasonable to achieve a high degree of effectiveness .
Johnson & Johnson: COVID-19 vaccine may start production in March next year
Johnson & Johnson recently suspended the Phase III clinical trial after a subject had a serious adverse reaction. However, the US Data and Safety Supervision Commission believes that there is no evidence to prove that the COVID-19 vaccine in the trial caused the adverse effects. Response, Johnson & Johnson has restarted Phase III clinical trials.
The South African pharmaceutical company Aspen also cooperated with Johnson & Johnson to complete the production, packaging and distribution of the COVID-19 vaccine in South Africa. The estimated output is 300 million doses per year. If the vaccine is proven effective, it is expected to be in March or April next year. Production started in December.
Novavax Pharmaceuticals: COVID-19 vaccine obtains FDA fast track qualification
The third phase of the US Novavax Pharmaceutical (Novavax) trial was launched in the United Kingdom at the end of September. Novavax said that the third phase of the trial is expected to be carried out in the United States and Mexico at the end of November, and the third phase will be launched as early as 2021. The interim efficacy data of the trial will be released in the first quarter.
Novavax has received US$1.6 billion support from the US government for the development and production of the COVID-19 vaccine. According to the agreement, Novavax will provide 100 million doses of the COVID-19 vaccine by the end of 2020. Novavax also issued a statement stating that the new coronavirus vaccine NVX-CoV2373 developed by the U.S. Food and Drug Administration (FDA) granted fast-track qualification.
China National Pharmaceutical Group: Emergency vaccination for hundreds of thousands of people, no serious adverse reactions
China National Pharmaceutical Group Sinopharm has developed two COVID-19 vaccines, and both of them have entered phase III trials. International Phase III clinical trials are currently being carried out in more than ten countries and regions including the UAE, Bahrain, Egypt, and more than 50,000 people have been vaccinated. The production plants for the two vaccines have been completed and the production capacity is expected to reach more than 1 billion doses next year.
China National Pharmaceutical Group Chairman Liu Jingzhen also revealed on November 6 that after the emergency use of the COVID-19 vaccine was approved in July this year, hundreds of thousands of people have been vaccinated urgently with the COVID-19 vaccine under Sinopharm Group. There is no serious adverse reaction. 56,000 people left the country after being vaccinated, and there were no cases of infection. The factory has been set up. By the end of this year, the production capacity will reach about 100 million doses.
Cancino: The first group of subjects was vaccinated in Mexico
On November 7th, the Chinese pharmaceutical company CanSino and the Academy of Military Medicine of the Academy of Military Sciences jointly developed a recombinant COVID-19 vaccine (adenovirus vector) in Mexico to start a phase three clinical trial, and the first group of subjects were vaccinated Vaccination, and will provide Mexico with 35 million doses of the COVID-19 vaccine from the end of 2020 to 2021.
Kexing Biotechnology: Has fully started the production of the COVID-19 inactivated vaccine
Sinovac Biotech is currently carrying out Phase III clinical trials in Brazil, Indonesia and other countries. The inactivated COVID-19 vaccine developed may be launched in 2021. According to Yin Weidong, Chairman of Sinovac Biotech, this After the vaccine, the body’s immunity is maintained for at least 6 months.
Gao Qiang, general manager of Kexing Biotechnology Co., Ltd., also said that there are no serious adverse reactions related to vaccines, and the production of inactivated COVID-19 vaccines has now been fully launched. By the end of the year, approximately 100 million doses of inactivated COVID-19 vaccine (including semi-finished products) can be produced.”
AstraZeneca: Start clinical trials in China within the year
AstraZeneca Life Science in the United Kingdom was also temporarily suspended due to severe adverse reactions in subjects, but the US Food and Drug Administration (FDA) has approved the resumption of Phase III clinical trials of the COVID-19 vaccine in the United States, in the United Kingdom and South Africa. Clinical trials in Brazil, Brazil and other places have also been resumed. Currently, approximately 23,000 participants have been recruited in the United Kingdom, Brazil, South Africa and the United States.
AstraZeneca Global Executive Vice President and China President Wang Lei revealed in an interview with Lu Media recently that the COVID-19 vaccine developed by AstraZeneca and Oxford University will start Phase I and Phase II clinical trials in China within this year, and will wait for Phase III clinical trials abroad in 2021. After the conclusion, it is expected to submit a listing application in Mainland China.
Russia’s “Sputnik-V”: 19,000 Russians have completed the first dose of vaccination
Russia’s first COVID-19 vaccine “Sputnik-V” was developed by the Gamaleya Research Institute of Epidemiology and Microbiology in Moscow and has entered the phase III clinical trial.
According to the “Deutsche Welle” report, the Gamalian Epidemiological Institute and the funded Russian Direct Investment Fund (RDIF) announced in a joint statement that the effectiveness of the “Sputnik V” vaccine is 92%, but , Because Russia has not provided relevant scientific research materials so far, it has also been questioned for falsifying data.
RIA Novosti reported that about 19,000 Russians have completed the first dose of vaccination, of which about 6,500 have completed the first and second doses. Early test results published in the British medical journal “The Lancet” showed that “Satellite V” caused all participants to have an antibody response, but large-scale long-term trials are still needed to ensure long-term safety Sex and effectiveness.
